|
SK55593A3
(en)
|
1991-03-05 |
1993-10-06 |
Wellcome Found |
Expresion of recombinant proteins in attenuated bacteria
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5961974A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
DK0897983T3
(da)
|
1991-10-25 |
2003-08-11 |
Immunex Corp |
Antistoffer mod CD40-L
|
|
US5716805A
(en)
*
|
1991-10-25 |
1998-02-10 |
Immunex Corporation |
Methods of preparing soluble, oligomeric proteins
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US5540926A
(en)
*
|
1992-09-04 |
1996-07-30 |
Bristol-Myers Squibb Company |
Soluble and its use in B cell stimulation
|
|
EP0659086B1
(en)
|
1992-09-04 |
1998-11-11 |
The University of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
JP4242447B2
(ja)
*
|
1993-01-22 |
2009-03-25 |
イミュネックス・コーポレーション |
Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
ATE309267T1
(de)
*
|
1994-04-28 |
2005-11-15 |
Boehringer Ingelheim Pharma |
Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
|
|
PT812206E
(pt)
|
1995-03-01 |
2002-11-29 |
Immunex Corp |
Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
|
|
NZ311335A
(en)
|
1995-06-07 |
1998-05-27 |
Immunex Corp |
Cd40l muteins and their use as ligands
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
EP1059932A1
(en)
|
1997-12-19 |
2000-12-20 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
ATE403728T1
(de)
|
1998-09-04 |
2008-08-15 |
Emergent Product Dev Uk Ltd |
Attenuierte salmonella spi2 mutante als antigen- träger
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
IL144952A0
(en)
|
1999-04-16 |
2002-06-30 |
Hoffmann La Roche |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
|
US7118751B1
(en)
*
|
1999-10-14 |
2006-10-10 |
Trubion Pharmaceuticals, Inc. |
DNA vaccines encoding antigen linked to a domain that binds CD40
|
|
DK1112747T3
(da)
|
1999-12-28 |
2004-10-25 |
Akzo Nobel Nv |
Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
|
|
EP1255560B1
(en)
|
2000-02-02 |
2008-10-29 |
UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE |
Cd40 ligand adjuvant for respiratory syncytial virus vaccine
|
|
BR0109322A
(pt)
|
2000-03-17 |
2002-12-10 |
Upjohn Co |
Materiais e métodos de vacina de salmonella
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
WO2002000232A2
(en)
|
2000-06-26 |
2002-01-03 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
ATE438710T1
(de)
|
2001-05-15 |
2009-08-15 |
Ortho Mcneil Janssen Pharm |
Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
|
|
US7462707B1
(en)
*
|
2001-07-06 |
2008-12-09 |
University Of Technology, Sydney |
Nucleic acids encoding a recombinant 250 kDa antigen from sporozoites/merozoites of Eimeria maxima and their uses
|
|
ZA200400479B
(en)
*
|
2001-07-06 |
2006-05-31 |
Abic Biolog Lab Teva |
Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
WO2003028441A1
(en)
|
2001-10-02 |
2003-04-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene therapy for the prevention of autoimmune disease
|
|
AU2002359780B2
(en)
*
|
2001-12-21 |
2009-08-13 |
Immunex Corporation |
Recombinant polypeptides
|
|
ATE421249T1
(de)
*
|
2002-02-13 |
2009-02-15 |
Immunology Lab Inc |
Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP2380440B1
(en)
|
2002-04-15 |
2016-03-09 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
EP1673389A2
(en)
|
2003-10-10 |
2006-06-28 |
Xencor Inc. |
Novel variants of cd40l protein
|
|
CA2548347A1
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
DE602005025005D1
(de)
|
2004-10-07 |
2011-01-05 |
Argos Therapeutics Inc |
Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
US20060286074A1
(en)
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
PT1949913E
(pt)
|
2005-10-07 |
2010-08-24 |
Proyecto Biomedicina Cima Sl |
Associação imunoestimuladora para a profilaxia e o tratamento da hepatite c
|
|
AU2006311752A1
(en)
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
DE102005054643B3
(de)
|
2005-11-10 |
2007-02-15 |
Assa Abloy Sicherheitstechnik Gmbh |
Schließzylinder
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
CU23576A1
(es)
*
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007106073A2
(en)
|
2006-03-02 |
2007-09-20 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
FR2898905B1
(fr)
*
|
2006-03-24 |
2008-05-09 |
Rhodia Recherches & Tech |
Composition polyisocyanate a proprietes anti-chocs ameliorees
|
|
US20090246220A1
(en)
*
|
2006-08-28 |
2009-10-01 |
Ertl Hildegund C J |
Constructs for enhancing immune responses
|
|
EP2517723B1
(en)
*
|
2006-09-18 |
2019-11-06 |
The Board of Trustees of The University of Arkansas |
Compositions and methods of enhancing immune responses
|
|
US20100292309A1
(en)
|
2007-03-08 |
2010-11-18 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
CN101024076B
(zh)
*
|
2007-03-29 |
2010-08-18 |
中国农业大学 |
球虫的新用途
|
|
EP2484691B1
(en)
*
|
2007-07-10 |
2016-01-13 |
Apogenix GmbH |
TNF superfamily collectin fusion proteins
|
|
BRPI0818736A2
(pt)
|
2007-10-30 |
2017-06-13 |
Univ Arkansas |
composições e métodos para intensificar imunorrepostas à bactéria flagelada
|
|
WO2009059298A2
(en)
*
|
2007-11-01 |
2009-05-07 |
Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancinc immune responses to eimeria
|
|
PL2604693T3
(pl)
*
|
2008-07-21 |
2016-09-30 |
|
Jednołańcuchowe cząsteczki TNFSF
|
|
US8316310B2
(en)
|
2008-08-05 |
2012-11-20 |
International Business Machines Corporation |
System and method for human identification proof for use in virtual environments
|
|
PT2184229E
(pt)
*
|
2008-11-11 |
2012-12-20 |
Agustawestland Spa |
Rotor de helicóptero
|
|
US20100150958A1
(en)
*
|
2008-12-15 |
2010-06-17 |
Vectogen Pty Ltd. |
Methods and Compositions for Use of a Coccidiosis Vaccine
|
|
CN102811734B
(zh)
*
|
2010-01-21 |
2016-02-10 |
阿肯色大学评议会 |
增强免疫应答的疫苗载体和方法
|
|
KR102434073B1
(ko)
*
|
2011-10-11 |
2022-08-18 |
비엘라 바이오, 인크. |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
|
WO2014043215A1
(en)
*
|
2012-09-11 |
2014-03-20 |
The Texas A&M University System |
Bi-specifc diabodies for masking and targeting vaccines
|
|
EA031234B1
(ru)
*
|
2012-10-29 |
2018-12-28 |
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас |
Вакцина с адъювантом на основе маннозилированного хитозана
|
|
HUE047484T2
(hu)
*
|
2013-02-14 |
2020-04-28 |
Univ Arkansas |
Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
|
|
US10376571B2
(en)
*
|
2013-03-15 |
2019-08-13 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to enteric pathogens
|
|
SG11201609965XA
(en)
*
|
2014-06-05 |
2016-12-29 |
Univ Arkansas |
Antibody guided vaccines and methods of use for generation of rapid mature immune responses
|
|
US20160090603A1
(en)
*
|
2014-09-30 |
2016-03-31 |
Sandia Corporation |
Delivery platforms for the domestication of algae and plants
|
|
US20190112380A1
(en)
*
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
SMT202100721T1
(it)
*
|
2016-05-27 |
2022-01-10 |
Abbvie Biotherapeutics Inc |
Anticorpi anti-cd40 e loro usi
|
|
IL264439B2
(en)
*
|
2016-08-17 |
2024-08-01 |
Factor Bioscience Inc |
non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
|